EMA/222887/2015

European Medicines Agency decision

P/0079/2015

of 10 April 2015

on the granting of a product specific waiver for ezetimibe / atorvastatin (calcium trihydrate) (Atozet and associated names, Kexrolt and associated names, Orvatez and associated names, Tioblis and associated names) (EMEA-001204-PIP02-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

European Medicines Agency decision

P/0079/2015

of 10 April 2015

on the granting of a product specific waiver for ezetimibe / atorvastatin (calcium trihydrate) (Atozet and associated names, Kexrolt and associated names, Orvatez and associated names, Tioblis and associated names) (EMEA-001204-PIP02-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Merck Sharp & Dohme Ltd on 18 November 2014 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 March 2015 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.

(2) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A waiver for ezetimibe / atorvastatin (calcium trihydrate) (Atozet and associated names, Kexrolt and associated names, Orvatez and associated names, Tioblis and associated names), film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Merck Sharp & Dohme Ltd, Clos du Lynx 5, 1200 – Brussels, Belgium.

Done at London, 10 April 2015

For the European Medicines Agency
Jordi Llinares Garcia
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/794985/2014
London, 20 March 2015

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMEA-001204-PIP02-14

Scope of the application

Active substance(s):

Ezetimibe / Atorvastatin (calcium trihydrate)

Invented name:

Atozet and associated names, Kexrolt and associated names, Orvatez and associated names, Tioblis and associated names

Condition(s):

Prevention of coronary artery disease

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme Ltd

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme Ltd submitted to the European Medicines Agency on 18 November 2014 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 20 January 2015.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

    1. to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

    The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Prevention of coronary artery disease

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age;
- for film-coated tablet, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of heterozygous hypercholesterolaemia and mixed hyperlipidaemia

Authorised indication(s):

1. Adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:

   - patients not appropriately controlled with a statin alone

   - patients already treated with a statin and ezetimibe

2. Treatment of homozygous familial hypercholesterolaemia

Authorised indication(s):

1. Adjunctive therapy to diet for use in adults with homozygous familial hypercholesterolaemia. Patients may also receive adjunctive treatments (e.g., low-density lipoprotein [LDL] apheresis).

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use